Business
Sema4 and Mount Sinai Use Integrative Network Analysis to Identify Potential New Lung Cancer Therapy
STAMFORD, Conn., April 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an artificial intelligence (AI)-driven genomic and clinical data intelligence
About this update from Genedx Holdings Corp.
[{"type":"text","content":"STAMFORD, Conn., April 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an artificial intelligence (AI)-driven genomic and clinical data intelligence platform company, and researchers from the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) in New York, NY recently published a study in Nature Communications using network modeling to identify novel targets for treating patients with early-stage invasive lung adenocarcinoma. “This new paper demonstrates how the synergism of in silico, in vitro, and in vivo technologies can accelerate the drug discovery process,” said Eric Schadt, PhD, Founder and Chief Executive Officer of Sema4 and an author on the paper. “By performing an integrative network analysis of early-stage lung adenocarcinoma, together with our partners at Icahn Mount Sinai, we were able to identify a gene expression signature capable of stratifying patients for treatment and a potential novel therapeutic for these patients.” “The approaches to diagnosing and treating early-stage lung adenocarcinoma are evolving and are based upon advances in understanding the biology and clinical activities of these tumors,” said senior author Charles Powell, MD, MBA, Janice and Coleman Rabin Professor of Medicine and Chief of Pulmonary, Critical Care and Sleep Medicine at Icahn Mount Sinai. “Our work using novel network approaches in collaboration with Sema4 to identify signatures of invasiveness and to identify drugs that can intercept progression of these cancers should contribute to advancing the understanding and outcomes for this cancer.” Lung adenocarcinoma is the most common lung cancer in the United States. Because of its often aggressive nature, early diagnosis is critical to improving survival. The new study disentangles the molecular mechanisms underlying tumor invasion in early-stage lung adenocarcinoma to improve patients’ diagnosis, prognosis, and treatment. “Sema4’s advanced predictive modeling and data science expertise uniquely position us to deliver value to and accelerate discovery for collaborators in the biopharma, healthcare, and research worlds,” said Gustavo Stolovitzky, PhD, Chief Science Officer at Sema4. “Through this collaboration, we again proved the value of our integrative network modeling by uncovering a novel way to stratify early-stage lung adenocarcinomas into indolent and aggressive fo...